NCT04432298View on ClinicalTrials.gov

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 20, 2020

Primary Completion Date

March 22, 2021

Study Completion Date

March 22, 2021

Conditions
COVID-19
Interventions
DRUG

Pamrevlumab

Sterile liquid for injection

DRUG

Placebo

Sterile liquid for injection

Trial Locations (4)

19107

Research Center, Philadelphia

19140

Research Center, Philadelphia

27403

Research Center, Greensboro

48202

Research Center, Detroit

Sponsors

Lead Sponsor

FibroGen
All Listed Sponsors
lead

FibroGen

INDUSTRY

NCT04432298 - Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease | Biotech Hunter | Biotech Hunter